Citigroup Inc Evolus, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Evolus, Inc. stock. As of the latest transaction made, Citigroup Inc holds 45,588 shares of EOLS stock, worth $496,453. This represents 0.0% of its overall portfolio holdings.

Number of Shares

45,588

Previous 19,114 138.51%

Holding current value

$496,453

Previous $207,000 256.52%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$10.66 - $17.48 $282,212 - $462,765	26,474 Added 138.51%	45,588 $738,000
Q2 2024 Aug 12, 2024	BUY	$10.45 - $13.76 $65,166 - $85,807	6,236 Added 48.42%	19,114 $207,000
Q1 2024 May 10, 2024	SELL	$9.99 - $14.91 $10,789 - $16,102	-1,080 Reduced 7.74%	12,878 $180,000
Q4 2023 Feb 09, 2024	BUY	$7.6 - $10.53 $60,708 - $84,113	7,988 Added 133.8%	13,958 $146,000
Q3 2023 Nov 09, 2023	SELL	$7.15 - $10.2 $60,074 - $85,700	-8,402 Reduced 58.46%	5,970 $54,000
Q2 2023 Aug 10, 2023	BUY	$7.23 - $10.52 $92,623 - $134,771	12,811 Added 820.69%	14,372 $104,000
Q1 2023 May 11, 2023	SELL	$7.81 - $11.05 $2,007 - $2,839	-257 Reduced 14.14%	1,561 $13,000
Q4 2022 Feb 09, 2023	SELL	$6.52 - $8.95 $55,745 - $76,522	-8,550 Reduced 82.47%	1,818 $13,000
Q3 2022 Nov 10, 2022	SELL	$7.76 - $13.72 $10,538 - $18,631	-1,358 Reduced 11.58%	10,368 $83,000
Q2 2022 Aug 10, 2022	BUY	$10.22 - $13.94 $95,730 - $130,575	9,367 Added 397.08%	11,726 $136,000
Q1 2022 May 12, 2022	SELL	$5.22 - $11.78 $41,086 - $92,720	-7,871 Reduced 76.94%	2,359 $26,000
Q4 2021 Feb 10, 2022	BUY	$5.37 - $8.38 $27,601 - $43,073	5,140 Added 100.98%	10,230 $67,000
Q3 2021 Nov 10, 2021	BUY	$7.36 - $13.67 $37,462 - $69,580	5,090 New	5,090 $39,000

Others Institutions Holding EOLS

# of Institutions

168

Shares Held

47.8M

Call Options Held

130K

Put Options Held

51K

View Full List

About Evolus, Inc.

Ticker EOLS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 56,094,800
Market Cap $611M
Description
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...

More about EOLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account